All About Multiple Sclerosis

More MS news articles for March 2003

Pharmacokinetic properties, induction of interferon, and efficacy of selected 5-halo-6-phenyl pyrimidinones, bropirimine analogues, in a model of severe experimental autoimmune encephalomyelitis

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12609460&dopt=Abstract

Int J Immunopharmacol 1999 Oct;21(10):647-62
Vroegop SM, Chapman DL, Decker DE, Galinet LA, Brideau RJ, Ready KA, Dunn CJ, Buxser SE.
Discovery Technologies, Pharmacia & Upjohn, Inc., Kalamazoo, USA

We showed previously that a 5-halo-6-phenyl-pyrimidinone, bropirimine (PNU-54461), inhibited progression of severe experimental autoimmune encephalomyelitis (EAE), an animal model of human multiple sclerosis.

In the work presented here, we examined the activity of a group of chemically-related bropirimine analogues.

First, the pharmacokinetic properties of the bropirimine analogues were examined in normal mice following oral dosing.

After equal oral doses, both PNU-56169 and PNU-63693 were found in the blood of normal mice at equal or higher concentrations than bropirimine, but PNU-54462 and PNU-56359 were present in blood only at very low concentrations.

Next, we examined the bropirimine analogues for activity in our model of severe EAE.

At a dose of 400 mg/kg administered orally every second day PNU-56169 nearly completely blocked EAE progression, but was ineffective at 100 mg/kg.

PNU-63693 was effective in EAE at concentrations of 200 mg/kg, 100 mg/kg, 50 mg/kg, and as low as 25 mg/kg.

Histopathology was examined by observing leukocyte infiltration into the lower spinal cords of the mice.

Treatment with 400 mg/kg of PNU-56169 and doses of 25, 50, 100, and 200 mg/kg of PNU-63693 significantly inhibited leukocyte infiltration into the lower spinal cord of treated mice in a dose-dependent manner.

Orally administered PNU-56169 and PNU-63693 also stimulated significant concentrations of IFNalpha in the serum of treated mice, which may be related to the efficacy of the compounds in EAE.

However, the correlation between IFNalpha in the blood and efficacy in treating EAE was not exact.

Thus, PNU-56169 and PNU-63693 were delivered to the blood following oral dosing, induced significant concentrations of IFNalpha in the blood, and were equally or more potent than PNU-54461 in inhibiting clinical signs of EAE.

The results suggest that 5-halo-6-phenyl-pyrimidinones are an interesting class of compounds to investigate for development in the treatment of multiple sclerosis.